Project description
Multipotent antibacterial vaccine
Antibiotic resistance is an emerging medical problem of global significance, threatening the treatment of bacterial infections using conventional drugs. Funded by the European Innovation Council, the PARAGON NOVEL VACCINE project has developed a novel immunotherapy that targets glyeraldehyde-3-phosphate dehydrogenase (GAPDH), a protein that suppresses host immunity by inducing an early production of interleukin-10, a potent anti-inflammatory cytokine. It is a peptide-based vaccine that blocks the bacterial GAPDH without interfering with the human analogue and treats infection from all invasive serotypes of five different bacterial strains. The project aims to further develop and test the innovative vaccine following promising preclinical data.
Objective
Immunethep has developed, patented (WO/2015/189422), and successfully undergone preclinical trials for a new breakthrough vaccine (PNV-Paragon Novel Vaccine). It protects against bacterial infections caused by 5 different bacteria: S. aureus, S. pneumoniae, K. pneumoniae, E. coli and GBS. Our innovation relies on the discovery of a virulence and immunosuppressive mechanism common to these pathogens. The bacteria excrete a highly immunosuppressive protein designated as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which disables the host immune response to infection. PNV works by blocking bacterial GAPDH, while not reacting to human GAPDH, allowing the host immune system to fight infection and eliminate the bacteria. Preclinical trials demonstrated high levels of efficacy against any of the 5 bacteria with an excellent safety profile. PNV is the world’s first vaccine not only to prevent multiple bacterial infections but for all invasive serotypes, including multi-resistant strains.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesbasic medicineimmunologyimmunisation
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
You need to log in or register to use this function
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
EIC-ACC - EIC-ACCCoordinator
3060 197 CANTANHEDE
Portugal
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.